Skip to main content
Search form
Search
Medicines for Malaria Venture
Developing antimalarials to save lives
Research & Development
MMV-supported projects
R&D areas of work
Next-generation medicines
Products for key populations
Working with regulators
Information for scientists
Call for proposals
TPPs & TCPs
Learning resources for discovery scientists
Project of the year award
Computational chemistry
Global health compound design webinars
R&D challenges
Access
Products & projects
Areas of work
Supporting introduction
Enhancing reach
Informing R&D
Gathering market intelligence
Product maps
Tool Kits
Injectable Artesunate tool kit
Artesunate rectal capsules tool kit
Seasonal Malaria Chemoprevention tool kit
The road to health impact
Access challenges
Partnering
Our partner network
The PDP model
Socially responsible agreements
Our clinical centre partners
Our donors
Current donors
Past donors
Donate to MMV
Our impact
Achievements
Real life stories
Better medicines for children
Malaria and COVID-19
About us
What we do
An overview of our work
Our strategic focus
Our history
People & governance
Staff bios
Staff map
Staff interviews
Board of Directors
MMV North America Board
Expert Scientific Advisory Committee
Access & Product Management Advisory Committee
Global Safety Board
Work with us
Jobs
RFPs/RFIs
MMV's internship programme
Policies
Diversity at MMV
Funding and expenditure
FAQs
Contact us
Malaria & medicines
Definitions and symptoms
Five species
Parasite lifecycle
Malaria facts & figures
Malaria treatment
History of antimalarials
Optimizing artemisinin production
Malaria online course
Newsroom
News & Press Releases
Films
Infographics
Interviews
Image slideshows
Publications
Audio
Events
MMV Open
Malaria
Libre
About Malaria
Libre
Participate in Malaria
Libre
Malaria
Libre
data repository
COVID Box
About the COVID Box
Request the COVID box
Supporting information
COVID Box terms and conditions
Pandemic Response Box
About the Pandemic Response Box
Request the Pandemic Response Box
Supporting information
Terms & conditions
Pathogen Box
About the Pathogen Box
Exploiting the Pathogen Box
Pathogen Box research
Supporting information
Terms & conditions
Malaria Box
About the Malaria Box
Malaria Box Research
Supporting information
Terms & conditions
Map of box orders
Follow-up guidelines
Open Source Drug Discovery
MMV Open Team
Contact us
Home
Newsroom
Press releases
Press releases
Filter
All
R&D
Donors
General
Open source
Partner
Access & product management
All
R&D
Donors
General
Open source
Partner
Access & product management
152 found
New report demonstrates how R&D partnerships serving neglected communities have developed dozens of life-saving innovations since 2010
28 Jan 2021
GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with
Plasmodium vivax
malaria accepted by Australian Therapeutic Goods Administration
08 Jan 2021
MMV supports the launch of the new Fight the Fakes Alliance
07 Dec 2020
Largest clinical trial in Africa to treat COVID-19 cases before they become severe
20 Nov 2020
GSK and MMV present positive data on treatment of
Plasmodium vivax
malaria
19 Nov 2020
Endemic countries in South America meet to discuss new tools for malaria elimination
02 Nov 2020
Global call to boost access to lifesaving malaria treatment for pregnant women in Africa
15 Oct 2020
MMV launches the COVID Box to stimulate new drug research
10 Jun 2020
This World Malaria Day MMV supports Swiss Malaria Group's call for urgent action
25 Apr 2020
Thailand becomes first malaria-endemic country in Asia-Pacific to approve tafenoquine for radical cure of
P. vivax
malaria
24 Apr 2020
MMV and LSTM collaborate to fill data gap on use of antimalarials during pregnancy
08 Mar 2020
International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa
03 Mar 2020
Research for new drugs against neglected diseases and malaria in Brazil to receive funding boost totaling BRL 43.5 million
27 Nov 2019
Country leaders pledge to boost malaria innovation and access to new and existing antimalarials
11 Nov 2019
Brazil becomes first malaria-endemic country to approve single-dose tafenoquine (Kozenis) for radical cure of
P. vivax
malaria
30 Oct 2019
Life-saving malaria project in Zambia to expand
25 Apr 2019
PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria
23 Apr 2019
Europe-Africa partnership spearheads development of next-generation antimalarial drug
15 Apr 2019
MMV and DND
i
make 400 compounds available to stimulate research into new drugs for pandemic diseases
29 Jan 2019
Two positive phase III studies of tafenoquine for the radical cure of
Plasmodium vivax
malaria published in The New England Journal of Medicine
16 Jan 2019
World Malaria Report highlights importance of country-led efforts to defeat malaria in highest burden countries
19 Nov 2018
Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of
P. vivax
malaria
21 Sep 2018
Severe malaria case fatality reduced by 96% in pilot project in Zambia led by Transaid, MMV and partners
28 Aug 2018
US FDA approves
Krintafel
(tafenoquine) for the radical cure of
P. vivax
malaria
20 Jul 2018
US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of
P. vivax
malaria
12 Jul 2018
WHO provides first-ever approval for rectal artesunate product for severe malaria
27 Feb 2018
GSK submits US regulatory application for single-dose tafenoquine for
Plasmodium vivax
malaria
28 Nov 2017
KAF156 enters phase IIb combination studies
21 Aug 2017
Cipla launches quality-assured Rectal Artesunate Suppositories for severe malaria in young children
25 Jul 2017
Three MMV-supported antimalarials listed as essential medicines
16 Jun 2017
MMV and GSK announce positive headline phase III results showing single-dose tafenoquine reduces risk of relapse in patients with
Plasmodium vivax
malaria
12 Jun 2017
MMV and Zydus join forces to develop new antimalarial
27 Sep 2016
UCT-H3D, MMV and international partners identify second potent antimalarial candidate
27 Jul 2016
MMV and Novartis expand partnership
15 Jun 2016
Netherlands-based consortium teams up with MMV in world-leading malaria translational research programme
25 Apr 2016
MMV joins Swiss Malaria Group in Bern to commemorate World Malaria Day
25 Apr 2016
Pyramax® granules (pyronaridine-artesunate) for children added to WHO list of prequalified medicines
20 Apr 2016
MMV announces collaborative agreement with S Kant HEALTHCARE Ltd
10 Mar 2016
Pyramax® Granules becomes first paediatric antimalarial to receive EMA Article 58 positive scientific opinion
20 Nov 2015
MMV provides QIMR Berghofer AU$10 M for malaria drug development
08 Nov 2015
GHIT invests $10.7 million in malaria, TB, leishmaniasis and dengue research
05 Nov 2015
New study details safety and efficacy of re-treatment with Pyramax®
23 Oct 2015
New compound has the potential to treat malaria patients in a single dose
17 Jun 2015
GHIT, Takeda and MMV progress first-in-class antimalarial DSM265 to patient trials in Peruvian Amazon
05 Jun 2015
Merck Serono and MMV sign agreement to develop potential antimalarial therapy
01 Apr 2015
Japanese global health fund announces new investment in promising compounds for antimalarial drug discovery
05 Feb 2015
Independent Safety Monitoring Board assessment enables recruitment of 2-5 year olds into OZ439/PQP Phase IIb trial
20 Jan 2015
MMV announces collaborations with Cipla and Strides
27 Nov 2014
GSK and MMV announce start of Phase III programme of tafenoquine
28 Apr 2014
Potential new antimalarial drug identified at the University of Dundee
06 Feb 2014
Breakthrough Therapy designation for potential new anti-relapse medicine for malaria
20 Dec 2013
Campaign launched to help eliminate malaria deaths
23 Sep 2013
Australian first to advance malaria medicines
19 Aug 2013
Japan launches bold effort to fight neglected diseases
31 May 2013
Winners of malaria photo contest announced
22 Apr 2013
Japan’s First PPP to Spearhead Innovation in Global Health
08 Apr 2013
Open access initiative reveals drug hits for deadly neglected tropical diseases
13 Nov 2012
African antimalarial research bears first fruit
28 Aug 2012
MMV assesses risk of resistance
22 Aug 2012
Delivery of child-friendly antimalarial hits the 100 million mark
22 Feb 2012
Pages
1
2
3
next ›
last »